[
  {
    "title": "Johnson & Johnson (JNJ) Stock Moves -0.54%: What You Should Know",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-stock-moves-214517992.html"
  },
  {
    "title": "Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results",
    "link": "https://finance.yahoo.com/news/johnson-johnson-host-investor-conference-204300751.html"
  },
  {
    "title": "Boston Scientific ends TAVR sales; J&J shares Monarch robot data",
    "link": "https://finance.yahoo.com/news/boston-scientific-ends-tavr-sales-140813976.html"
  },
  {
    "title": "1 Top Dividend Stock to Buy for a Lifetime of Passive Income",
    "link": "https://finance.yahoo.com/news/1-top-dividend-stock-buy-113000674.html"
  },
  {
    "title": "US FDA Votes in Favor of Benefit-Risk Profile of Johnson & Johnson’s DARZALEX FASPRO",
    "link": "https://finance.yahoo.com/news/us-fda-votes-favor-benefit-110747734.html"
  },
  {
    "title": "Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and Beyond",
    "link": "https://finance.yahoo.com/news/generating-passive-income-3-top-081600391.html"
  },
  {
    "title": "Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-declines-more-214504338.html"
  },
  {
    "title": "JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges",
    "link": "https://finance.yahoo.com/news/jnj-down-6-3-months-130700419.html"
  },
  {
    "title": "CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success",
    "link": "https://finance.yahoo.com/news/cgon-stock-rallies-27-month-124600748.html"
  },
  {
    "title": "Johnson & Johnson MedTech introduces ultrasound catheter for cardiac ablation",
    "link": "https://finance.yahoo.com/news/johnson-johnson-medtech-introduces-ultrasound-092001532.html"
  },
  {
    "title": "Johnson & Johnson (NYSE:JNJ) FDA Panel Supports DARZALEX FASPRO®? for High-Risk Multiple Myeloma",
    "link": "https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-fda-173312979.html"
  },
  {
    "title": "Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know",
    "link": "https://finance.yahoo.com/news/investors-heavily-search-johnson-johnson-130015774.html"
  },
  {
    "title": "Johnson & Johnson's (NYSE:JNJ) Shareholders Will Receive A Bigger Dividend Than Last Year",
    "link": "https://finance.yahoo.com/news/johnson-johnsons-nyse-jnj-shareholders-124931908.html"
  },
  {
    "title": "Johnson & Johnson (NYSE:JNJ) Hit with $147M Verdict in Landmark Antitrust Case Over Reprocessed Medical Devices",
    "link": "https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-hit-032143317.html"
  },
  {
    "title": "U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma",
    "link": "https://finance.yahoo.com/news/u-fda-oncologic-drugs-advisory-222100442.html"
  },
  {
    "title": "J&J subsidiary ordered to pay $147M for violating antitrust rules",
    "link": "https://finance.yahoo.com/news/j-j-subsidiary-ordered-pay-101651632.html"
  },
  {
    "title": "Innovative Health awarded $147m in antitrust lawsuit against J&J’s Biosense Webster",
    "link": "https://finance.yahoo.com/news/innovative-health-awarded-147m-antitrust-160958675.html"
  },
  {
    "title": "Intravascular lithotripsy: market competition and clinical potential",
    "link": "https://finance.yahoo.com/news/intravascular-lithotripsy-market-competition-clinical-130801565.html"
  },
  {
    "title": "Dividend Hikes Offer Optimism Amid Tariff Turmoil",
    "link": "https://finance.yahoo.com/news/dividend-hikes-offer-optimism-amid-192541239.html"
  },
  {
    "title": "US States Likely to Defy US Downgrade to Keep Top Credit Ratings",
    "link": "https://finance.yahoo.com/news/us-states-likely-defy-us-163315923.html"
  },
  {
    "title": "Trump administration not backing down on Big Pharma pressure campaign",
    "link": "https://finance.yahoo.com/news/trump-administration-not-backing-down-on-big-pharma-pressure-campaign-133031848.html"
  },
  {
    "title": "3 Magnificent Stocks That Are Passive Income Machines",
    "link": "https://finance.yahoo.com/news/3-magnificent-stocks-passive-income-104000270.html"
  },
  {
    "title": "Jim Cramer Notes That “People Are Staying Away From” Johnson & Johnson",
    "link": "https://finance.yahoo.com/news/jim-cramer-notes-people-staying-190819606.html"
  },
  {
    "title": "Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock",
    "link": "https://finance.yahoo.com/news/heres-why-johnson-johnson-jnj-134011487.html"
  },
  {
    "title": "Why Is Johnson & Johnson (JNJ) Down 4.9% Since Last Earnings Report?",
    "link": "https://finance.yahoo.com/news/why-johnson-johnson-jnj-down-153006479.html"
  },
  {
    "title": "Halozyme, J&J slide as analyst cuts rating on CMS draft guidance",
    "link": "https://finance.yahoo.com/news/halozyme-j-j-slide-analyst-150056315.html"
  },
  {
    "title": "The Smartest Dividend Stocks to Buy With $5,000 Right Now",
    "link": "https://finance.yahoo.com/news/smartest-dividend-stocks-buy-5-014100369.html"
  },
  {
    "title": "Is Johnson & Johnson (JNJ) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom?",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-best-pharma-210812185.html"
  },
  {
    "title": "Big Pharma Counted on This Loophole. It May Be Closing.",
    "link": "https://finance.yahoo.com/m/d95d463e-940e-36ae-83f4-c6ed28659541/big-pharma-counted-on-this.html"
  },
  {
    "title": "Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News",
    "link": "https://finance.yahoo.com/m/7df79c49-fe62-3f8a-bfdf-4dd9d624b63f/top-biotech-halozyme.html"
  },
  {
    "title": "With the breakneck speed of cancer breakthroughs, oncologists feel left behind. Can Big Pharma chime in?",
    "link": "https://finance.yahoo.com/news/breakneck-speed-cancer-breakthroughs-oncologists-080000879.html"
  },
  {
    "title": "S&P, Dow Pharma Stocks Boomerang On Drug-Pricing Order That Is 'All Bark' And 'Little Bite'",
    "link": "https://finance.yahoo.com/m/8bbeb00f-58ab-3bfb-8fe9-492a82597341/s-p-dow-pharma-stocks.html"
  },
  {
    "title": "HistoSonics secures first insurance coverage for histotripsy system",
    "link": "https://finance.yahoo.com/news/histosonics-secures-first-insurance-coverage-164238878.html"
  },
  {
    "title": "Trump expected to sign order to slash US drug prices",
    "link": "https://finance.yahoo.com/video/trump-expected-sign-order-slash-144432389.html"
  },
  {
    "title": "Mag 7 rally, airline & pharmaceutical stocks: Trending Tickers",
    "link": "https://finance.yahoo.com/video/mag-7-rally-airline-pharmaceutical-140147890.html"
  },
  {
    "title": "US-China trade truce, April CPI, drug prices: 3 Things",
    "link": "https://finance.yahoo.com/video/us-china-trade-truce-april-130939738.html"
  },
  {
    "title": "Pharma Shares Fall Pre-Bell Following Plan by Trump to Reduce US Prescription Drug Prices",
    "link": "https://finance.yahoo.com/news/pharma-shares-fall-pre-bell-095515844.html"
  },
  {
    "title": "J&J reports new data from Phase III trial of icotrokinra for plaque psoriasis",
    "link": "https://finance.yahoo.com/news/j-j-reports-data-phase-092051813.html"
  },
  {
    "title": "Is Johnson & Johnson (JNJ) the Best Income Stock to Invest in Now?",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-best-income-080901144.html"
  },
  {
    "title": "Johnson & Johnson (NYSE:JNJ) Announces Positive Trial Results Amid Legal Setback",
    "link": "https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-announces-172248816.html"
  },
  {
    "title": "J&J's oral psoriasis drug helps patients achieve clear skin in late-stage study",
    "link": "https://finance.yahoo.com/news/j-js-skin-disease-drug-121405243.html"
  },
  {
    "title": "Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis",
    "link": "https://finance.yahoo.com/news/icotrokinra-results-show-significant-skin-120500752.html"
  },
  {
    "title": "Is Johnson & Johnson (JNJ) the Best Medical Device Stock to Buy Now?",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-best-medical-103324862.html"
  },
  {
    "title": "Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...",
    "link": "https://finance.yahoo.com/news/zymeworks-inc-zyme-q1-2025-074531091.html"
  },
  {
    "title": "A Look at Pharma ETFs After Strong Q1 Earnings",
    "link": "https://finance.yahoo.com/news/look-pharma-etfs-strong-q1-155000613.html"
  },
  {
    "title": "Listerine, Tylenol Maker Kenvue Tops Estimates, Lifts Net Sales Outlook",
    "link": "https://finance.yahoo.com/news/listerine-tylenol-maker-kenvue-tops-122200309.html"
  },
  {
    "title": "Johnson & Johnson expands efforts to champion the nursing workforce globally",
    "link": "https://finance.yahoo.com/news/johnson-johnson-expands-efforts-champion-121200671.html"
  },
  {
    "title": "FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight",
    "link": "https://finance.yahoo.com/news/fda-expands-surprise-inspections-foreign-185407796.html"
  },
  {
    "title": "Is Johnson & Johnson (JNJ) the Best Dow Stock?",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-best-dow-182827915.html"
  },
  {
    "title": "J&J Medtech survey finds strong European support for healthcare data sharing",
    "link": "https://finance.yahoo.com/news/j-j-medtech-survey-finds-164957153.html"
  },
  {
    "title": "The Zacks Analyst Blog Highlights Johnson & Johnson and AbbVie",
    "link": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-johnson-124800331.html"
  },
  {
    "title": "Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better.",
    "link": "https://finance.yahoo.com/m/a4bec800-6f4b-30e9-8edf-e6305a9166c4/trump-is-threatening-big.html"
  },
  {
    "title": "Johnson & Johnson (NYSE:JNJ) Presents Promising TREMFYA Study Results At Digestive Disease Week 2025",
    "link": "https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-presents-173924195.html"
  },
  {
    "title": "The Zacks Analyst Blog Highlights GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific",
    "link": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-ge-131000432.html"
  },
  {
    "title": "Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock",
    "link": "https://finance.yahoo.com/news/know-beyond-why-johnson-johnson-130016315.html"
  },
  {
    "title": "JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects?",
    "link": "https://finance.yahoo.com/news/jnj-vs-abbv-pharma-powerhouse-122600727.html"
  },
  {
    "title": "Johnson & Johnson (NYSE:JNJ) Is Paying Out A Larger Dividend Than Last Year",
    "link": "https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-paying-111728520.html"
  },
  {
    "title": "ChatGPT Stock Advice: Johnson & Johnson (JNJ) Among Top Stock Recommendations",
    "link": "https://finance.yahoo.com/news/chatgpt-stock-advice-johnson-johnson-091214426.html"
  },
  {
    "title": "MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know",
    "link": "https://finance.yahoo.com/news/medtechs-adjust-2025-outlook-amid-190000027.html"
  },
  {
    "title": "Was Jim Cramer Right About Johnson & Johnson (JNJ)?",
    "link": "https://finance.yahoo.com/news/jim-cramer-johnson-johnson-jnj-132922006.html"
  },
  {
    "title": "TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks",
    "link": "https://finance.yahoo.com/news/tremfya-guselkumab-positioned-become-first-120500064.html"
  },
  {
    "title": "TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years",
    "link": "https://finance.yahoo.com/news/tremfya-guselkumab-delivers-sustained-clinical-120500832.html"
  },
  {
    "title": "If You Invested $10K In Johnson & Johnson Stock 10 Years Ago, How Much Would You Have Now?",
    "link": "https://finance.yahoo.com/news/invested-10k-johnson-johnson-stock-031644133.html"
  },
  {
    "title": "Is Johnson & Johnson (JNJ) The Most Profitable Cheap Stock to Buy Now?",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-most-profitable-151926091.html"
  },
  {
    "title": "Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?",
    "link": "https://finance.yahoo.com/news/trump-administration-cause-abbvie-eli-084900783.html"
  },
  {
    "title": "Q1 earnings pulse check: companies tentative on pharma-specific tariffs",
    "link": "https://finance.yahoo.com/news/q1-earnings-pulse-check-companies-150624060.html"
  },
  {
    "title": "'Declare victory and move on': Eli Lilly CEO on Trump tariff threat",
    "link": "https://finance.yahoo.com/news/declare-victory-and-move-on-eli-lilly-ceo-on-trump-tariff-threat-160646465.html"
  },
  {
    "title": "Pharma downplays tariff threat, even as risks remain unclear",
    "link": "https://finance.yahoo.com/news/pharma-downplays-tariff-threat-even-122400598.html"
  },
  {
    "title": "If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?",
    "link": "https://finance.yahoo.com/m/d615c35b-9343-3e67-975a-923b1fe5cf7b/if-a-recession-hits-will.html"
  },
  {
    "title": "FDA approves J&J’s Imaavy for generalised myasthenia gravis",
    "link": "https://finance.yahoo.com/news/fda-approves-j-j-imaavy-104009306.html"
  },
  {
    "title": "The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis",
    "link": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-amazon-084900432.html"
  },
  {
    "title": "Trump Says Tariffs Politically Risky, But He’s Not Rushing Deals",
    "link": "https://finance.yahoo.com/news/trump-says-tariffs-politically-risky-014826903.html"
  },
  {
    "title": "Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems",
    "link": "https://finance.yahoo.com/news/top-stock-reports-amazon-com-210200739.html"
  },
  {
    "title": "Johnson & Johnson (JNJ): Jim Cramer Says “They Love the Weak Dollar” — Is This Quiet Giant Back in Favor?",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-jim-cramer-201708830.html"
  },
  {
    "title": "Is Johnson & Johnson (JNJ) the Best Dow Stock for the Next 12 Months?",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-best-dow-182817266.html"
  },
  {
    "title": "Johnson & Johnson (NYSE:JNJ) Gains FDA Approval For IMAAVY™ To Treat Myasthenia Gravis",
    "link": "https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-gains-173051884.html"
  },
  {
    "title": "Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)",
    "link": "https://finance.yahoo.com/news/johnson-johnson-receives-fda-approval-122900395.html"
  },
  {
    "title": "4 PFA studies in the spotlight at Heart Rhythm 2025",
    "link": "https://finance.yahoo.com/news/4-pfa-studies-spotlight-heart-151007224.html"
  },
  {
    "title": "Johnson & Johnson (JNJ): Among the Best Long-Term Dividend Stocks to Buy According to Billionaires",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-among-best-123324365.html"
  },
  {
    "title": "Johnson & Johnson (JNJ): Among the Most Profitable Blue Chip Stocks to Buy Now",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-among-most-204421394.html"
  },
  {
    "title": "CG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer Drug",
    "link": "https://finance.yahoo.com/m/f15fb010-5cb9-3f71-bd15-1b129aeb091b/cg-oncology-soars-on-its.html"
  },
  {
    "title": "New data from J&J’s bladder cancer drug-device trial strengthens support for NDA",
    "link": "https://finance.yahoo.com/news/data-j-j-bladder-cancer-173607463.html"
  },
  {
    "title": "Jim Cramer Says Trump Administration Should Intervene in Johnson & Johnson (JNJ) Legal Issues – ‘Where Are Capitalist Instincts Here?’",
    "link": "https://finance.yahoo.com/news/jim-cramer-says-trump-administration-152011733.html"
  },
  {
    "title": "J&J’s Tremfya gains EC marketing authorisation for ulcerative colitis",
    "link": "https://finance.yahoo.com/news/j-j-tremfya-gains-ec-144409352.html"
  },
  {
    "title": "Jim Cramer Says You Should Buy Johnson & Johnson (JNJ), Thinks Talc Problems ‘Behind It’",
    "link": "https://finance.yahoo.com/news/jim-cramer-says-buy-johnson-200110201.html"
  },
  {
    "title": "Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC",
    "link": "https://finance.yahoo.com/news/johnson-johnsons-tar-200-monotherapy-180000630.html"
  },
  {
    "title": "Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer",
    "link": "https://finance.yahoo.com/news/johnson-johnsons-tar-200-monotherapy-175000318.html"
  },
  {
    "title": "These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?",
    "link": "https://finance.yahoo.com/news/2-top-dividend-stocks-making-141500161.html"
  },
  {
    "title": "Is Johnson & Johnson (JNJ) the Best Safe Stock to Buy According to Hedge Funds?",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-best-safe-125945633.html"
  },
  {
    "title": "Johnson & Johnson (JNJ) Soared as Markets Favored Defensive Sector",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-soared-markets-112950762.html"
  },
  {
    "title": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-attracting-investor-130015092.html"
  },
  {
    "title": "3 Dividend Kings That Have Raised Their Payouts in 2025",
    "link": "https://finance.yahoo.com/news/3-dividend-kings-raised-payouts-123400821.html"
  },
  {
    "title": "In the Wake of the Trump Tariff Crash: 2 Unparalleled Dividend Stocks to Buy at a Discount Right Now",
    "link": "https://finance.yahoo.com/news/wake-trump-tariff-crash-2-075100708.html"
  },
  {
    "title": "Jim Cramer on Johnson & Johnson (JNJ): ‘A Good Quarter — Market Finally Cares’",
    "link": "https://finance.yahoo.com/news/jim-cramer-johnson-johnson-jnj-011927169.html"
  },
  {
    "title": "Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term",
    "link": "https://finance.yahoo.com/news/why-johnson-johnson-jnj-top-134008764.html"
  },
  {
    "title": "European pharma companies push for higher drug prices in EU amid U.S. tariff threats",
    "link": "https://finance.yahoo.com/news/novartis-sanofi-ceos-eu-raise-064420389.html"
  },
  {
    "title": "JNJ Q1 Earnings: Pipeline Progress and MedTech Execution Drive Guidance Above Expectations",
    "link": "https://finance.yahoo.com/news/jnj-q1-earnings-pipeline-progress-025433130.html"
  },
  {
    "title": "Why Johnson & Johnson, Chevron, And Flowers Foods Are Winners For Passive Income",
    "link": "https://finance.yahoo.com/news/why-johnson-johnson-chevron-flowers-020108180.html"
  },
  {
    "title": "Johnson & Johnson (NYSE:JNJ) Showcases Paradigm-Shifting Bladder Cancer Trials at AUA 2025",
    "link": "https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-showcases-172815984.html"
  },
  {
    "title": "Johnson & Johnson's (NYSE:JNJ) Dividend Will Be Increased To $1.30",
    "link": "https://finance.yahoo.com/news/johnson-johnsons-nyse-jnj-dividend-105831087.html"
  },
  {
    "title": "Is Johnson & Johnson (JNJ) the Best American Dividend Stock to Buy According to Analysts?",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-best-american-142258434.html"
  },
  {
    "title": "Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA",
    "link": "https://finance.yahoo.com/news/johnson-johnson-unveils-highly-anticipated-133600157.html"
  },
  {
    "title": "Healthcare ETFs Tug of War: Insurers Tumble, Pharma Surges",
    "link": "https://finance.yahoo.com/news/healthcare-etfs-tug-war-insurers-123000090.html"
  },
  {
    "title": "Is Johnson & Johnson (JNJ) the Best Low Volatility Stock to Buy Now?",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-best-low-132007388.html"
  },
  {
    "title": "2 Recession-Proof Stocks to Buy With a Better Credit Rating Than the U.S. Government",
    "link": "https://finance.yahoo.com/news/2-recession-proof-stocks-buy-113000511.html"
  },
  {
    "title": "From $50 A Month To $1M Portfolio — Investor Shares Top 10 Holdings, Says 'Finally Reached $1M!' Thanks To Relentless Discipline",
    "link": "https://finance.yahoo.com/news/50-month-1m-portfolio-investor-010159336.html"
  },
  {
    "title": "Johnson & Johnson (JNJ): Among Value Stocks in Ken Fisher’s Portfolio",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-among-value-154227056.html"
  },
  {
    "title": "3 Top Dividend Stocks Yielding Over 3% to Buy With $500 Right Now",
    "link": "https://finance.yahoo.com/news/3-top-dividend-stocks-yielding-143000717.html"
  },
  {
    "title": "Jim Cramer on Johnson & Johnson (JNJ): Tariff-Proof, Drug-Driven, and Still a Buy",
    "link": "https://finance.yahoo.com/news/jim-cramer-johnson-johnson-jnj-190852776.html"
  },
  {
    "title": "Johnson & Johnson Pivots Its AI Strategy",
    "link": "https://finance.yahoo.com/m/a4799b8d-98b1-3e93-9101-c31b261d18bf/johnson-johnson-pivots-its.html"
  },
  {
    "title": "How To Put $100 In Your Retirement Fund Each Month With Johnson & Johnson Stock",
    "link": "https://finance.yahoo.com/news/put-100-retirement-fund-month-020116463.html"
  },
  {
    "title": "Johnson & Johnson (JNJ): Among the Innovative Healthcare Stocks to Watch in 2025",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-among-innovative-145132221.html"
  },
  {
    "title": "Here's How You Should Play JNJ Stock After Q1 Earnings Beat",
    "link": "https://finance.yahoo.com/news/heres-play-jnj-stock-q1-120300626.html"
  },
  {
    "title": "Netflix stock has been nearly unscathed by Trump tariffs. Some think it could be Silicon Valley’s version of Johnson & Johnson",
    "link": "https://finance.yahoo.com/news/netflix-stock-nearly-unscathed-trump-110500893.html"
  },
  {
    "title": "This Super-Safe High-Yield Stock Just Extended Its Dividend Growth Streak to 63 Years in a Row",
    "link": "https://finance.yahoo.com/news/super-safe-high-yield-stock-080700318.html"
  },
  {
    "title": "Buy These Defensive Stocks After Beating Earnings Expectations?: ACI, JNJ",
    "link": "https://finance.yahoo.com/news/buy-defensive-stocks-beating-earnings-223500505.html"
  },
  {
    "title": "J&J’s electrophysiology sales dip amid slow Varipulse start",
    "link": "https://finance.yahoo.com/news/j-j-electrophysiology-sales-dip-162800444.html"
  },
  {
    "title": "Big banks report Q1 beats, China stops taking Boeing deliveries: Morning Buzz",
    "link": "https://finance.yahoo.com/news/big-banks-report-q1-beats-155936913.html"
  },
  {
    "title": "Needham upgrades Boston Scientific on easing competition, growth opportunities",
    "link": "https://finance.yahoo.com/news/needham-upgrades-boston-scientific-easing-152436271.html"
  },
  {
    "title": "Is Johnson & Johnson (JNJ) the Best Dividend Monarch to Invest in Now?",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-best-dividend-151919763.html"
  },
  {
    "title": "ETFs in Focus Post JNJ's Q1 Earnings Beat, Dividend Hike",
    "link": "https://finance.yahoo.com/news/etfs-focus-post-jnjs-q1-140000330.html"
  },
  {
    "title": "Jim Cramer: Johnson & Johnson (JNJ) Is a “Great American Company with a AAA Balance Sheet”",
    "link": "https://finance.yahoo.com/news/jim-cramer-johnson-johnson-jnj-133137612.html"
  },
  {
    "title": "Johnson & Johnson (JNJ) Q1 2025 Earnings Call Highlights: Strong Sales Growth Amid STELARA ...",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-q1-2025-070055505.html"
  },
  {
    "title": "Stocks fizzle after two-day rally driven by bank earnings and tech",
    "link": "https://finance.yahoo.com/news/wall-street-banks-cashing-trade-123249767.html"
  },
  {
    "title": "These Stocks Moved the Most Today: Bank of America, Citigroup, Netflix, Boeing, Tesla, HPE, Applied Digital, and More",
    "link": "https://finance.yahoo.com/m/4acd1581-8487-308e-9a2a-48ddeb05703c/these-stocks-moved-the-most.html"
  },
  {
    "title": "J&J expects a $400M hit from tariffs, mostly from China",
    "link": "https://finance.yahoo.com/video/j-j-expects-400m-hit-194926931.html"
  },
  {
    "title": "J&J Forecasts $400 Million in Tariff-Related Costs This Year",
    "link": "https://finance.yahoo.com/m/99cc1f40-f58d-3f24-b134-22a5c0860954/j-j-forecasts-400-million-in.html"
  },
  {
    "title": "Johnson & Johnson (JNJ): Stuck in a Range but Ready to Break Out if Legal Clouds Clear – Jim Cramer Weighs In",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-stuck-range-190144848.html"
  },
  {
    "title": "J&J projects $400m tariff hit but raises sales outlook",
    "link": "https://finance.yahoo.com/news/j-j-projects-400m-tariff-184011718.html"
  },
  {
    "title": "Equities Little Changed Intraday After Corporate Earnings",
    "link": "https://finance.yahoo.com/news/equities-little-changed-intraday-corporate-180750271.html"
  },
  {
    "title": "Johnson & Johnson (NYSE:JNJ) Increases Dividend and Reports Strong Q1 Earnings Growth",
    "link": "https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-increases-173039383.html"
  },
  {
    "title": "J&J beat on earnings, but tariffs still pressure pharma sector",
    "link": "https://finance.yahoo.com/video/j-j-beat-earnings-tariffs-163000679.html"
  },
  {
    "title": "J&J sees tariff impact from exports to China more than global imports: CFO",
    "link": "https://finance.yahoo.com/news/jj-sees-tariff-impact-from-exports-to-china-more-than-global-imports-cfo-155153851.html"
  },
  {
    "title": "Top Midday Stories: Elliott Takes Stake of Over $1.5 Billion in HP Enterprise; Johnson & Johnson Lifts Sales Outlook",
    "link": "https://finance.yahoo.com/news/top-midday-stories-elliott-takes-155050555.html"
  },
  {
    "title": "Johnson & Johnson expects $400 million in tariff-related costs, mostly related to China",
    "link": "https://finance.yahoo.com/news/johnson-johnson-expects-400-million-152058261.html"
  },
  {
    "title": "Citi and BofA earnings, Johnson & Johnson, China blocks Boeing",
    "link": "https://finance.yahoo.com/video/citi-bofa-earnings-johnson-johnson-151532919.html"
  },
  {
    "title": "JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal",
    "link": "https://finance.yahoo.com/news/jnj-tops-q1-earnings-ups-151400715.html"
  },
  {
    "title": "J&J Boosts Outlook Despite Incoming Tariff Costs",
    "link": "https://finance.yahoo.com/m/7587a6b8-41b1-38a1-b035-d05170727a2f/j-j-boosts-outlook-despite.html"
  },
  {
    "title": "Import Prices Turn Negative for First Time Since September",
    "link": "https://finance.yahoo.com/news/import-prices-turn-negative-first-150400878.html"
  },
  {
    "title": "Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations",
    "link": "https://finance.yahoo.com/m/cbffbae0-c324-3c1f-8b01-8215d56751a7/why-johnson-johnson-stock.html"
  },
  {
    "title": "Import Prices, Empire State Come In Mild; Q1 Earnings Beats Abound",
    "link": "https://finance.yahoo.com/news/import-prices-empire-state-come-141900578.html"
  },
  {
    "title": "Johnson & Johnson Raises Sales Outlook as Pharma Sales Lead Q1 Beat",
    "link": "https://finance.yahoo.com/news/johnson-johnson-raises-sales-outlook-134755490.html"
  },
  {
    "title": "Compared to Estimates, Johnson & Johnson (JNJ) Q1 Earnings: A Look at Key Metrics",
    "link": "https://finance.yahoo.com/news/compared-estimates-johnson-johnson-jnj-133005341.html"
  },
  {
    "title": "Johnson & Johnson Raises Full-Year Sales Guidance Following First-Quarter Beat",
    "link": "https://finance.yahoo.com/news/johnson-johnson-raises-full-sales-132003194.html"
  },
  {
    "title": "Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit",
    "link": "https://finance.yahoo.com/news/johnson-johnson-q1-earnings-strong-130910174.html"
  },
  {
    "title": "NYSE Content Advisory: Pre-Market update + Bank of America beats earnings estimates",
    "link": "https://finance.yahoo.com/news/nyse-content-advisory-pre-market-125500437.html"
  },
  {
    "title": "Wall Street Digests Earnings as US Equity Futures Drop Pre-Bell",
    "link": "https://finance.yahoo.com/news/wall-street-digests-earnings-us-125405080.html"
  },
  {
    "title": "J&J Flexes Its Financial 'Bicep,' Hiking Guidance Despite Tariff Headwinds",
    "link": "https://finance.yahoo.com/m/48557d5a-e21b-3608-a439-d3fa2d5d866d/j-j-flexes-its-financial.html"
  },
  {
    "title": "Bank of America, Citigroup, Johnson & Johnson: Stocks to watch today",
    "link": "https://finance.yahoo.com/news/bank-america-citigroup-johnson-johnson-124404678.html"
  },
  {
    "title": "Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke",
    "link": "https://finance.yahoo.com/news/novartis-nvs-unleashes-23bn-strategic-120841357.html"
  },
  {
    "title": "J&J expects tariff charge of $400M this year",
    "link": "https://finance.yahoo.com/news/j-j-pegs-tariff-costs-120400925.html"
  },
  {
    "title": "J&J keeps forecasts steady as pharma confronts tariff threat",
    "link": "https://finance.yahoo.com/news/j-j-keeps-forecasts-steady-115500791.html"
  },
  {
    "title": "5 Things to Know Before the Stock Market Opens",
    "link": "https://finance.yahoo.com/news/5-things-know-stock-market-115415953.html"
  },
  {
    "title": "Johnson & Johnson (JNJ) Q1 Earnings and Revenues Beat Estimates",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-q1-earnings-113502444.html"
  },
  {
    "title": "Trade, Earnings Nudge Wall Street Higher Pre-Bell; Asia, Europe Gain",
    "link": "https://finance.yahoo.com/news/trade-earnings-nudge-wall-street-110605836.html"
  },
  {
    "title": "Johnson & Johnson Tops Q1 Estimates, Lifts Full-Year Sales Outlook",
    "link": "https://finance.yahoo.com/news/johnson-johnson-tops-q1-estimates-103555590.html"
  },
  {
    "title": "Johnson & Johnson’s (NYSE:JNJ) Q1 Sales Top Estimates, Full-Year Sales Guidance is Optimistic",
    "link": "https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-q1-103228260.html"
  },
  {
    "title": "Johnson & Johnson: Q1 Earnings Snapshot",
    "link": "https://finance.yahoo.com/news/johnson-johnson-q1-earnings-snapshot-102959858.html"
  },
  {
    "title": "Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%",
    "link": "https://finance.yahoo.com/news/johnson-johnson-announces-63rd-consecutive-102500447.html"
  },
  {
    "title": "Johnson & Johnson CEO warns US tariffs may disrupt drug supply",
    "link": "https://finance.yahoo.com/news/j-j-beats-wall-street-102325376.html"
  },
  {
    "title": "Johnson & Johnson Reports Q1 2025 Results",
    "link": "https://finance.yahoo.com/news/johnson-johnson-reports-q1-2025-102000108.html"
  },
  {
    "title": "J&J completes first surgeries with Ottava robot",
    "link": "https://finance.yahoo.com/news/j-j-completes-first-surgeries-094123636.html"
  },
  {
    "title": "Big Bank earnings, Fed commentary, tax deadline: What to Watch",
    "link": "https://finance.yahoo.com/video/big-bank-earnings-fed-commentary-230000867.html"
  },
  {
    "title": "Pfizer hits setback in obesity drug race as GLP-1 trial halts",
    "link": "https://finance.yahoo.com/video/pfizer-hits-setback-obesity-drug-214449466.html"
  },
  {
    "title": "Johnson & Johnson (JNJ) Reports Earnings Tomorrow: What To Expect",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-reports-earnings-161705076.html"
  },
  {
    "title": "Is Johnson & Johnson (JNJ) the Best Dividend Paying Stock According to Hedge Funds?",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-best-dividend-135058198.html"
  },
  {
    "title": "JPMorgan, Wells Fargo, Morgan Stanley, Netflix, UnitedHealthcare, Johnson & Johnson and CSX Corp are part of Zacks Earnings Preview",
    "link": "https://finance.yahoo.com/news/jpmorgan-wells-fargo-morgan-stanley-072200566.html"
  },
  {
    "title": "Novartis (NVS) Surges 4.0%: Is This an Indication of Further Gains?",
    "link": "https://finance.yahoo.com/news/novartis-nvs-surges-4-0-063000831.html"
  },
  {
    "title": "Why Johnson & Johnson (JNJ) is the Best Medical Stock to Buy According to Billionaires",
    "link": "https://finance.yahoo.com/news/why-johnson-johnson-jnj-best-214127916.html"
  },
  {
    "title": "Is Johnson & Johnson (NYSE:JNJ) a Cheap NYSE Stock to Invest in According to Hedge Funds?",
    "link": "https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-cheap-130522494.html"
  },
  {
    "title": "Jim Cramer on Johnson & Johnson (JNJ): AAA Balance Sheet… An Unjustified Casualty of Pharma Tariffs",
    "link": "https://finance.yahoo.com/news/jim-cramer-johnson-johnson-jnj-175902159.html"
  },
  {
    "title": "Buy, Sell or Hold J&J Stock? Key Tips Ahead of Q1 Earnings",
    "link": "https://finance.yahoo.com/news/buy-sell-hold-j-j-153200724.html"
  },
  {
    "title": "Stocks to watch this week: Goldman Sachs, TSMC, ASML, Netflix, LVMH and Sainsbury's",
    "link": "https://finance.yahoo.com/news/goldman-sachs-tsmc-asml-netflix-lvmh-and-sainsburys-stocks-to-watch-131111514.html"
  },
  {
    "title": "J&J reports analysis from Phase III trial of plaque psoriasis treatment",
    "link": "https://finance.yahoo.com/news/j-j-reports-analysis-phase-114155867.html"
  },
  {
    "title": "2 Top Dividend Stocks to Buy Right Now",
    "link": "https://finance.yahoo.com/news/2-top-dividend-stocks-buy-082500912.html"
  },
  {
    "title": "S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash",
    "link": "https://finance.yahoo.com/m/5788e167-ba2e-3f2d-8e9e-4bfb72e0e2c1/s-p-dow-jones-pharma-names.html"
  },
  {
    "title": "Seeking Clues to Johnson & Johnson (JNJ) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics",
    "link": "https://finance.yahoo.com/news/seeking-clues-johnson-johnson-jnj-131512923.html"
  },
  {
    "title": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-trending-stock-130015450.html"
  },
  {
    "title": "Jim Cramer’s Take On Johnson & Johnson (JNJ): Are Litigation Fears Creating a Rare Buying Opportunity?",
    "link": "https://finance.yahoo.com/news/jim-cramer-johnson-johnson-jnj-124243597.html"
  },
  {
    "title": "Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill",
    "link": "https://finance.yahoo.com/news/icotrokinra-results-show-75-adolescents-120500105.html"
  },
  {
    "title": "Stock Market Sell-Off Shopping Spree: 3 Top Dividend Stocks I Just Bought to Boost My Passive Income",
    "link": "https://finance.yahoo.com/news/stock-market-sell-off-shopping-091700793.html"
  },
  {
    "title": "The Dow Crashed 4,260 Points in 3 Days: Here Are 3 Dow Stocks That Make for No-Brainer Buys Right Now",
    "link": "https://finance.yahoo.com/news/dow-crashed-4-260-points-075100834.html"
  },
  {
    "title": "Johnson & Johnson (NYSE:JNJ) Shares React as FDA Grants Multiple Designations to Nipocalimab",
    "link": "https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-shares-180948855.html"
  },
  {
    "title": "Trump says pharmaceutical tariffs may be coming: What to know",
    "link": "https://finance.yahoo.com/video/trump-says-pharmaceutical-tariffs-may-141157823.html"
  },
  {
    "title": "Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs",
    "link": "https://finance.yahoo.com/m/f171bfb7-94e2-3b98-bde2-9d5add357a5c/novo-nordisk-abbvie-stocks.html"
  },
  {
    "title": "Johnson & Johnson (JNJ): Among Defensive Stocks Billionaire Ken Fisher is Betting On",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-among-defensive-221416769.html"
  },
  {
    "title": "Johnson & Johnson (JNJ) Stock Moves -0.52%: What You Should Know",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-stock-moves-214516665.html"
  },
  {
    "title": "Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients",
    "link": "https://finance.yahoo.com/news/johnson-johnsons-compelling-data-shows-182632656.html"
  },
  {
    "title": "Biopharma Shakeup: Goldman Boosts J&J, Eli Lilly While Flagging Risks at Pfizer and AbbVie",
    "link": "https://finance.yahoo.com/news/biopharma-shakeup-goldman-boosts-j-175813148.html"
  },
  {
    "title": "AAN 2025: J&J reveals data for nipocalimab, showing long-term disease control in MG",
    "link": "https://finance.yahoo.com/news/aan-2025-j-j-reveals-174440234.html"
  },
  {
    "title": "Walgreens, CVS, & US drugmakers make big moves: What to know",
    "link": "https://finance.yahoo.com/video/walgreens-cvs-us-drugmakers-big-140318681.html"
  },
  {
    "title": "Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?",
    "link": "https://finance.yahoo.com/news/johnson-johnson-jnj-expected-beat-140009002.html"
  },
  {
    "title": "J&J starts IVL trial in ‘difficult-to-cross’ coronary arteries",
    "link": "https://finance.yahoo.com/news/j-j-starts-ivl-trial-095730647.html"
  },
  {
    "title": "Johnson & Johnson Says New Data Support Nipocalimab's Long-Term Disease Control in Myasthenia Gravis",
    "link": "https://finance.yahoo.com/news/johnson-johnson-says-data-support-093034570.html"
  },
  {
    "title": "EC approves extension of indication for Janssen-Cilag’s Darzalex",
    "link": "https://finance.yahoo.com/news/ec-approves-extension-indication-janssen-085023254.html"
  },
  {
    "title": "Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)",
    "link": "https://finance.yahoo.com/news/johnson-johnson-highlights-data-showcase-070000555.html"
  },
  {
    "title": "J&J’s psoriatic arthritis therapy trial meets endpoints",
    "link": "https://finance.yahoo.com/news/johnson-johnson-trial-therapy-psoriatic-111209056.html"
  },
  {
    "title": "Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study",
    "link": "https://finance.yahoo.com/news/johnson-johnsons-tremfya-shows-efficacy-183530113.html"
  },
  {
    "title": "The Zacks Analyst Blog Highlights Johnson & Johnson and Pfizer",
    "link": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-johnson-130400151.html"
  },
  {
    "title": "TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis",
    "link": "https://finance.yahoo.com/news/tremfya-guselkumab-first-only-il-120500976.html"
  }
]